Shares of AbbVie and Johnson & Johnson took a hit Friday after FDA briefing documents hinted a cheaper competitor for the drug companies’ blockbuster anti-inflammatory treatments could be headed to market soon.
WSJ.com: Health, Wall Street Journal: Business: Health
Fri, 02/05/2016 - 5:54pm
Shares of AbbVie and Johnson & Johnson took a hit Friday after FDA briefing documents hinted a cheaper competitor for the drug companies’ blockbuster anti-inflammatory treatments could be headed to market soon.